Search

Product: Lonapegsomatropin-tcgd

Long-term Safety and Efficacy of Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial

Long-term Safety and Efficacy of Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial

medaffairinfus | May 19, 2026

Read More

Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results

medaffairinfus | February 9, 2026

Read More

Children With Growth Hormone Deficiency Treated With Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results

medaffairinfus | December 16, 2025

Read More

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children With Growth Hormone Deficiency: The fliGHt Trial

medaffairinfus | December 16, 2025

Read More

Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results

medaffairinfus | December 16, 2025

Read More

Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency

medaffairinfus | December 16, 2025

Read More

Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial

medaffairinfus | December 16, 2025

Read More

The Rationale and Design of TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency

medaffairinfus | December 16, 2025

Read More

A Phase 2 Trial of Long-Acting TransCon Growth Hormone in Adult GH Deficiency

medaffairinfus | December 16, 2025

Read More

A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency

medaffairinfus | December 16, 2025

Read More